SGK3 and prostate carcinoma: In keeping with this, SGK1, SGK2, and SGK3 are rarely mutated in prostate cancer (≤0.41%), whereas amplification occurs in up to 2.5%, 2.0%, and 20.3% of cases respectively (Tables S1–S3).